Certa Therapeutics

Executive Summary

Certa Therapeutics is a clinical-stage Australian biotech developing first-in-class oral small-molecule inhibitors of GPR68, a novel master-switch target in fibrosis. By blocking GPR68 activation, the company aims to intervene upstream of inflammatory and fibrotic pathways, offering a potentially disease-modifying approach for multiple fibrotic diseases. Certa's lead program targets systemic sclerosis, chronic kidney disease, diabetic nephropathy, and focal segmental glomerulosclerosis, all areas with high unmet medical need. Founded in 2020, the company has advanced to Phase 2 clinical development, leveraging over two decades of research on the GPR68 hypothesis. With a differentiated mechanism and a broad pipeline, Certa Therapeutics is positioned to address the core pathology of fibrosis across indications. The upcoming period is critical, with key catalysts including Phase 2 data readouts and potential regulatory milestones. If successful, Certa could become a leader in precision fibrosis therapy. The company's robust intellectual property and experienced management team further support its potential to deliver value to patients and investors. The conviction score reflects the promising preclinical and early clinical profile of GPR68 inhibition, albeit with the inherent risks of Phase 2 development.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Results in Systemic Sclerosis55% success
• Q1 2027FDA Meeting to Discuss Accelerated Approval Pathway for FSGS60% success
• Q2 2027Series C Financing to Support Phase 3 Preparations70% success